Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
Condition(s):Malignant Melanoma Stage IVLast Updated:January 26, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Malignant Melanoma Stage IVLast Updated:January 26, 2023Recruiting
Condition(s):Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Renal Cell CarcinomaLast Updated:March 12, 2024Recruiting
Condition(s):Renal Cell CarcinomaLast Updated:January 17, 2024Active, not recruiting
Condition(s):Cutaneous Toxicity From ICI TherapyLast Updated:May 24, 2021Completed
Condition(s):Colorectal NeoplasmsLast Updated:December 22, 2023Active, not recruiting
Condition(s):Metastatic Prostatic AdenocarcinomaLast Updated:June 21, 2022Completed
Condition(s):Metastatic CancerLast Updated:February 11, 2021Unknown status
Condition(s):Solid Tumor; Non Small Cell Lung Cancer; Neuroendocrine CarcinomaLast Updated:July 18, 2023Recruiting
Condition(s):Adult Solid TumorLast Updated:April 14, 2023Completed
Condition(s):Merkel Cell CarcinomaLast Updated:November 28, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.